Laborie Medical Technologies Acquires Pelvalon

Innovative product added to Laborie's growing portfolio that treats underserved patient community

Laborie Medical Technologies Corp. (Laborie) a specialist medical technology company, announced today that it has acquired Pelvalon, Inc., a privately held medical device company located in Redwood City, CA.

Pelvalon has developed an innovative product called the Eclipse™ System, a non-surgical, patient-controlled device for women suffering from fecal incontinence (FI). FI is a pelvic floor disorder that affects one in ten women. The Eclipse has a compelling clinical profile validated in multiple studies, is FDA-cleared and has established reimbursement. The product is simple, safe and effective and its reputation has spurred demand from numerous healthcare professionals and patients across the country.

“Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity,” said Michael Frazzette, President & CEO of Laborie. “Our mission is well served by the addition of Eclipse™ to help patients who suffer from this difficult condition.”

“I am grateful for the dedicated work of my colleagues to bring the therapy to this point, and we are delighted that Laborie will be able to scale and deliver Eclipse™ to the doctors and patients who need it,” said Miles Rosen, Pelvalon Founder and CEO. “Laborie’s mission aligns perfectly with this technology.”

“Patricia Industries is committed to supporting Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity,” said Yuriy Prilutskiy, Head of Patricia Industries North America, a part of Investor AB, and owner of Laborie. “This acquisition further supports Laborie’s long-term growth, leverages Patricia Industries’ healthcare and life sciences expertise and aligns with our organization’s purpose of creating value for people and society by building strong and sustainable businesses.”

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”